Please provide your email address to receive an email when new articles are posted on . Shockwave Medical announced that its intravascular lithotripsy catheter for treatment of calcified peripheral ...

New study findings show that utilizing super-high-pressure non-compliant balloons (NCB) is non-inferior to intravascular lithotripsy (IVL) balloon catheters for lesion preparation and stent expansion ...

Johnson & Johnson (NYSE:JNJ) is one of Navellier’s top long-term stock picks. On May 12, Johnson & Johnson (NYSE:JNJ) reaffirmed its push for opportunities in the treatment of calcified coronary ...

Boston Scientific Corporation (NYSE: BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary ...

Technique to prep calcified plaque produces good results on imaging ...

Please provide your email address to receive an email when new articles are posted on . Employing intravascular lithotripsy facilitated transcatheter mitral valve replacement in a patient with severe ...

Boston Scientific (NYSE:BSX) reported strong positive results from its pivotal FRACTURE IDE trial for the SEISMIQ 4CE ...

SAN FRANCISCO — The interventional answer to heavily calcified coronary lesions could reside in a balloon catheter that blasts calcifications with bursts of acoustic energy, suggests an early-stage ...

Boston Scientific Corporation BSX on Tuesday reported positive pivotal trial data for its investigational SEISMIQ 4CE ...

Boston Scientific (BSX) announced on Tuesday that its SEISMIQ 4CE catheter, an intravascular lithotripsy device designed to fracture calcium within coronary arteries, has been successful in a clinical ...

Standard endovascular treatment options for modifying calcium or plaque during percutaneous coronary intervention (PCI) include balloon angioplasty using standard or high-pressure non-compliant ...

Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass.